Methylpheophorbide is a chlorin derivative and a key intermediate in the biosynthesis of chlorophyll. It is formed through the enzymatic removal of the phytyl chain from chlorophyll. Methylpheophorbide is a potent photosensitizer, which means it can absorb light and transfer energy to other molecules, leading to chemical reactions. It has been investigated for its potential applications in photodynamic therapy (PDT), a treatment for cancer that uses light and photosensitizers to destroy tumor cells. Methylpheophorbide is also studied for its potential use in solar energy applications, due to its ability to absorb light efficiently. Research on methylpheophorbide aims to understand its properties and explore its potential uses in various fields.'
methylpheophorbide: split product of chlorophyll obtained by saponification of pheophytin; RN given refers to (3S-(3alpha,4beta,21beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73074 |
| CHEMBL ID | 1985396 |
| MeSH ID | M0101711 |
| Synonym |
|---|
| NCI60_003881 |
| nsc267041 |
| nsc-267041 |
| nsc-407320 |
| NSC407320 , |
| 3-phorbinepropanoic acid,8,13,18-tetramethyl-20-oxo-, methyl ester, [3s-(3.alpha.,4.beta.,21.beta.)]- |
| phaeophorbid a, methyl ester |
| 3-phorbinepropionic acid,8,13,18-tetramethyl-20-oxo-9-vinyl-, dimethyl ester |
| methyl phaeophorbide |
| 3-phorbinepropionic acid, 21-carboxy-14-ethyl-4,8,13,18-tetramethyl-20-oxo-9-vinyl-, dimethyl ester (van) |
| methylpheophorbide |
| methyl phaeophorbide a |
| methyl (3s-(3alpha,4beta,21beta))-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinylphorbine-3-propionate |
| nsc 407320 |
| einecs 227-007-3 |
| 3-phorbinepropanoic acid, 9-ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-, methyl ester, (3s-(3alpha,4beta,21beta))- |
| methylbacteriopheophorbide |
| methyl pheophorbide-a |
| IWKYEJKHXKRZIJ-UHFFFAOYSA-N |
| CHEMBL1985396 |
| methyl pheophorbide |
| BDUAKLHVCJVMNM-UHFFFAOYSA-N |
| methyl 16-ethenyl-11-ethyl-4-hydroxy-22-(3-methoxy-3-oxopropyl)-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaene-3-carboxylate |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||